US Approval for Novartis' Signifor - Analyst Blog

By
A A A

The US Food and Drug Administration ("FDA") recently approved Novartis' ( NVS ) Signifor (pasireotide) to treat adults suffering from Cushing's disease for whom pituitary surgery is not an option or has not been effective.

The approval from the US regulatory body did not come as a surprise as in November this year the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) gave a positive opinion on the use of Signifor as a treatment for Cushing's disease.

The FDA's decision was based on positive results from the phase III PASPORT-CUSHINGS (PASireotide clinical trial PORTfolio - CUSHING'S disease) study. Novartis conducted the study to evaluate the safety and efficacy of Signifor in 162 patients with recurrent Cushing's disease, and newly diagnosed patients with Cushing's disease for whom surgery is not recommended.


Results from the study showed that after treatment with Signifor, patients experienced lower urinary free cortisol (UFC) levels, a measure of disease control. The study also revealed that certain clinical manifestations of Cushing's disease tended towards improvement.

We remind investors that in April this year, Signifor was approved in the EU for the treatment of adults suffering from Cushing's disease who are either ineligible for surgery or have had unsuccessful surgeries. Novartis is currently looking to get the drug approved worldwide.

We are pleased with the US approval of the drug. Signifor, the first FDA approved medicine for the treatment of Cushing's disease, is sure to have a potential market in the US.

Other than Cushing's disease, Novartis is also evaluating Signifor in phase III studies for the treatment of acromegaly syndrome.

Currently, we have a Neutral recommendation on Novartis. Novartis carries a Zacks #3 Rank (Hold) in the short run. However, other pharma companies like Novo Nordisk ( NVO ) and Johnson & Johnson ( JNJ ) carry a Zacks #2 Rank (Buy).



JOHNSON & JOHNS (JNJ): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: JNJ , NVO , NVS

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

77%
50%
100%

Most Active by Volume

100,376,898
  • $17.62 ▲ 0.51%
83,231,837
  • $25.62 ▲ 1.91%
75,739,329
  • $111.78 ▼ 0.77%
65,297,937
  • $36.37 ▼ 1.76%
59,053,093
  • $47.66 ▲ 0.29%
53,482,350
  • $2.59 ▼ 0.38%
51,504,284
  • $7.34 ▲ 2.37%
51,434,656
  • $8.14 ▲ 6.96%
As of 12/19/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com